Pain neurobiology: nociceptors, channels and central sensitization
Background concepts · G1a · Reviewed by a board-certified pain physician on October 31, 2026
Bottom line
Nociception starts at channels such as Nav1.7 and TRPV1 and is amplified centrally; central sensitization explains allodynia and secondary hyperalgesia, and its mechanisms, like spinal immune signaling, can differ between sexes.
Key points
- Nav1.7 sets nociceptor excitability. Biallelic loss-of-function SCN9A mutations abolish Nav1.7 current and cause congenital inability to experience pain in otherwise healthy people 1; gain-of-function variants cause primary erythermalgia, burning red extremities 2.
- Nav1.7 also serves smell. It is required for synaptic signaling from olfactory sensory neurons, so Nav1.7-null patients are anosmic 3.
- CIPA is a different gene. Congenital insensitivity to pain with anhidrosis results from TRKA (NGF receptor) mutations and adds anhidrosis, unexplained fevers, self-mutilation and intellectual disability; it is autosomal recessive 4.
- TRPV1 explains capsaicin. High-concentration capsaicin activates TRPV1 on cutaneous nociceptors, causing burning, then reduces TRPV1-expressing nerve endings, which re-emerge over months 5.
- Central sensitization is CNS amplification. Woolf defines it operationally as amplified neural signaling within the CNS that elicits pain hypersensitivity: lower thresholds (allodynia), heightened responses (hyperalgesia) and receptive-field expansion (secondary hyperalgesia) 6.
- Spinal immune mechanisms differ by sex. In mice, microglia were required for nerve-injury hypersensitivity in males, whereas females relied on adaptive immune cells, likely T cells; microglia-targeting drugs worked only in males 7.
Watch for
Peripheral sensitization cannot account for dynamic tactile allodynia, temporal summation or secondary hyperalgesia; these point to central mechanisms, including pain that continues after the stimulus ends and spreads beyond the injury 6.
High-yield for the exam
- Windup is a progressive rise in dorsal horn output during a train of identical C-fiber stimuli, first described by Mendell and Wall in 1965 6.
- Central sensitization outlasts the conditioning input, persisting tens of minutes after it ends, unlike windup 6.
- Ketamine inhibits central temporal summation and secondary mechanical hyperalgesia, supporting an NMDA receptor role 6.
- Intradermal capsaicin produces tactile allodynia and secondary hyperalgesia used as a human model of central sensitization 6.
- Capsaicin 8% treatment is not repeated more often than every 3 months 5.
- Congenital inability to experience pain from SCN9A is autosomal recessive; primary erythermalgia from SCN9A is autosomal dominant 12.
- Cox's families carried homozygous nonsense SCN9A mutations; mutant channels gave currents no greater than background 1.
- Sorge and colleagues concluded that male animals cannot serve as proxies for females in pain research 7.
Numbers to know
| Item | Value |
|---|---|
| SCN9A protein | Nav1.7 1 |
| CIPA gene | TRKA, the NGF receptor 4 |
| Windup described | 1965 6 |
| Woolf's central sensitization study | 1983 6 |
| Conditioning burst in Woolf's model | ~10–20 seconds at 1–10 Hz 6 |
| Capsaicin 8% repeat interval | ≥3 months 5 |
| Cox families with SCN9A loss | 3 consanguineous families, northern Pakistan 1 |
Common traps
- Confusing Nav1.7 loss of function with CIPA; sweating and cognition are normal with Nav1.7 loss 14.
- Equating windup with central sensitization 6.
- Expecting an NMDA antagonist to dampen central sensitization without psychotomimetic effects; trials show little therapeutic index 6.
- Assuming a target validated only in male animals will work in women 7.
Practise this topic
5 more questions on this topic in the full question bank, with explanations and sources.
Sources
- Cox JJ, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature, 2006. pmc.ncbi.nlm.nih.gov/articles/PMC7212082/
- Yang Y, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet, 2004. pubmed.ncbi.nlm.nih.gov/14985375/
- Weiss J, et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature, 2011. pmc.ncbi.nlm.nih.gov/articles/PMC3674497/
- Indo Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet, 1996. pubmed.ncbi.nlm.nih.gov/8696348/
- US Food and Drug Administration. QUTENZA (capsaicin) 8% topical system prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad
- Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain, 2011. pmc.ncbi.nlm.nih.gov/articles/PMC3268359/
- Sorge RE, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci, 2015. pmc.ncbi.nlm.nih.gov/articles/PMC4772157/
Related topics
Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.